CD8A and neoplasm: Five of the strongest mesenchymal-related MHC class I mutant peptides (Table 1) were selected for (1) CD8+ T cell proliferation and cytotoxic responses against EO771-B7.1 ± miR-200c target cells in culture and (2) protection against EO771 tumor growth when delivered as a pooled vaccine in vivo.